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Purpose
We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean
patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not
requiring dialysis.
Materials and Methods
Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated
with everolimus or temsirolimus between January 2008 and December 2014 were included.
Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival
(OS) and progression-free survival (PFS) durations were evaluated according to the degree
of renal impairment.
Results
Eighteen patients were considered eligible for the study (median age, 59 years). The median
glomerular filtration rate was 51.5 mL/min/1.73 m2. The best response was partial 
response in six patients and stable disease in 11 patients. The median PFS and OS dura-
tions were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5
to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events
included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine
level.
Conclusion
Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in 
Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.
Key words
TOR serine-threonine kinases, Renal cell carcinoma, 
Renal insufficiency
Introduction
With advances in the understanding of biology and genet-
ics of metastatic renal cell carcinoma (mRCC), various tar-
geted agents were developed for its treatment. These drugs
targeted elements that inhibit the vascular endothelial
growth factor (VEGF) and mammalian target rapamycin
(mTOR) pathway [1-7].
Temsirolimus and everolimus are mTOR inhibitors used
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in treatment of mRCC. The mTOR pathway is an intracellu-
lar signaling pathway that regulates cellular metabolism,
growth, proliferation, and angiogenesis [3,8]. mTOR inhi-
bitors bind to an intracellular protein, FKBP-12, forming a
complex that inhibits the mTOR serine-threonine kinase
[2,3,9]. Temsirolimus is the standard first-line treatment for
patients with poor prognosis, and everolimus is the standard
second-line treatment for patients who progressed after
VEGF-targeted therapy [2-4].
End-stage renal disease (ESRD) patients are at increased
risk for developing cancer and at four-to-five fold increased
risk of developing renal cancer in their naïve kidney [10,11].
Diabetes and hypertension are independent risk factors for
development of renal cell carcinoma (RCC), and develop-
ment of chronic kidney disease is possible in patients receiv-
ing postsurgical therapy for RCC [12,13]. Several studies in
RCC patients with ESRD have been reported, however 
patients with chronic renal insufficiency not requiring dial-
ysis have not yet been studied [12,14,15]. Therefore, we stud-
ied mRCC patients with chronic renal insufficiency not
requiring dialysis. 
The purpose of this retrospective study was to evaluate the
efficacy and toxicity of mTOR inhibitors in Korean patients
with mRCC with chronic renal insufficiency not requiring
dialysis.
Materials and Methods
1. Patients and methods
We conducted a retrospective search for patients with
mRCC with chronic renal insufficiency not requiring dialysis
who had received the mTOR inhibitors everolimus or tem-
sirolimus between January 2008 and December 2014 at Yon-
sei Cancer Center and Busan Paik Hospital, in South Korea.
The Cockcroft-Gault formula was used for calculation of the
glomerular filtration rate (GFR). Patients with a GFR of  15
mL/min/1.73 m2 but < 60 mL/min/1.73 m2 were considered
eligible for analysis. The patients were divided into two
groups according to the degree of renal insufficiency, as 
defined by the National Kidney Foundation [24]: moderate
renal impairment (30 mL/min/1.73 m2  GFR < 60 mL/min/
1.73 m2) and severe renal impairment (15 mL/min/1.73 m2
 GFR < 30 mL/min/1.73 m2). The following clinical data
were obtained retrospectively: demographics (age and sex),
Eastern Cooperative Oncology Group (ECOG) performance
status, stage at diagnosis, prognostic risk group based on the
Memorial Sloane Kettering Cancer Center Criteria (MSKCC),
results after prior nephrectomy, and serum creatinine con-
centrations. The following data regarding mTOR inhibitors
were obtained: initial dose and schedule of mTOR inhibitors,
serum creatinine concentration during and after use of
mTOR inhibitors, dose reductions, and adverse events (AEs)
and abnormal laboratory findings graded according to the
National Cancer Institute Common Terminology Criteria for
AEs ver. 3.0. The best response defined according the 
Response Evaluation Criteria In Solid Tumors (RECIST), pro-
gression-free survival (PFS), and overall survival (OS) data
were also collected. PFS was defined as time from date of
first dose of mTOR inhibitors to the first documentation of
disease progression or death from any cause; OS was defined
as time from date of first dose of mTOR inhibitors to the final
documentation of death from any cause or to last follow-up.
The study was approved by the Protocol Review Committee
of the Korean Cancer Study Group (KCSG GU) 14-08.
2. Statistical analysis
Categorical data are presented as frequency counts and
percentages, and continuous variables, as medians and
ranges. PFS and OS durations were evaluated using the 
Kaplan-Meier method. Log-rank tests were used for compar-
ison of PFS and OS data between the two patient groups and
by mTOR inhibitor regimen (everolimus or temsirolimus).
All analyses were performed using SPSS ver. 22.0 (IBM Co.,
Armonk, NY).
Results
1. Patient characteristics
From both centers, 18 patients were eligible. Patient char-
acteristics are listed in Table 1. The median age at diagnosis
was 59 years. Fifteen patients had clear cell histology and
three patients had non-clear cell histology. All patients had
renal insufficiency at diagnosis of RCC. Eight of these 
patients had renal insufficiency due to hypertension and 
diabetes, but others had renal insufficiency due to unknown
causes. Sixteen patients had undergone prior nephrectomy.
The median GFR was 51.2 mL/min/1.73 m2. Sixteen patients
were classified as having moderate renal insufficiency and
two as having severe renal insufficiency. In the moderate
renal insufficiency group, five patients were treated with
mTOR inhibitors as a first-line treatment. Two patients in this
group were treated with bevacizumab plus temsirolimus due
to enrollment in a clinical trial, and two were treated with
temsirolimus due to non-clear cell histology. One patient in
this group was treated with everolimus due to enrollment in
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a clinical trial. Eleven patients were treated with mTOR 
inhibitors as a second-line treatment, including four who
were treated with temsirolimus and the others with
everolimus. All patients with severe renal impairment had
an ECOG performance status of 1 and had undergone prior
nephrectomy, although all patients presented with stage IV
disease at diagnosis.
All patients with severe renal impairment were treated
with everolimus as a second-line treatment. One patient was
treated with sunitnib as a first-line treatment, and another
with sorafenib. In the severe renal impairment group, the
median GFR of patients was 22 mL/min/1.73 m2. According
to MSKCC risk grouping, one patient with severe renal 
impairment had a favorable prognosis and one patient had
an intermediate prognosis.
2. Safety assessment of mTOR inhibitor treatment
The starting oral dose of everolimus was 10 mg daily for
10 patients and the starting intravenous dose for tem-
sirolimus was 25 mg weekly for eight patients in the overall
series. All patients were started on the original dose of mTOR
inhibitors regardless of GFR. In the moderate renal impair-
ment group, six patients treated with everolimus were dose
delayed due to non-renal toxicity, including one patient
treated with everolimus as a first-line treatment and the oth-
ers treated with everolimus as a second-line treatment. Three
patients treated with temsirolimus were dose delayed due to
non-renal toxicity, including one patient treated with tem-
sirolimus as a first-line treatment and two patients treated
with temsirolimus as a second-line treatment.
Table 1. Characteristics of mRCC patients with renal insufficiency
Characteristic Moderate renal impairment Severe renal impairment Total
Sex
Male 14 ( 1 ( 15 (
Female 2 ( 1 ( 3 (
Age at diagnosis, median (range, yr) 56 (44-81) 73.5 (73-74) 59 (
ECOG
0 9 ( 0 ( 9 (
1 7 ( 2 ( 9 (
Histology
Clear-cell 13 ( 2 ( 15 (
Non-clear cell 3 ( 0 ( 3 (
Stage at diagnosis
I 1 ( 0 ( 1 (
II 3 ( 0 ( 3 (
III 0 ( 0 ( 0 (
IV 10 ( 2 ( 12 (
Unknown 2 ( 0 ( 2 (
Prior nephrectomy 14 ( 2 ( 16 (
Underlying disease
Hypertension and diabetes 3 ( 1 (
Diabetes 3 ( 0 (
Hypertension 1 ( 0 (
Ccr level at start date of mTOR inhibitors, 51.9 (35-59.7) 22 (18-26) 51.2 (18-59.7)
median (range, mL/min/1.73m2)
MSKCC risk groups
Favorable 6 ( 1 ( 7 (
Intermediate 9 ( 1 ( 10 (
Poor 1 ( 0 ( 1 (
No. of prior regimens
0 5 ( 0 ( 5 (
1 11 ( 2 ( 13 (
mRCC, metastatic renal cell carcinoma; ECOG, Eastern Cooperative Oncology Group; Ccr, creatinine clearance; mTOR,
mammalian target rapamycin; MSKCC, Memorial Sloane Kettering Cancer Center Criteria.
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In the moderate renal insufficiency group, six patients had
dose reduction because of non-renal toxicity. Four of them
received everolimus as a second-line treatment, and two rec-
eived temsirolimus as a second-line treatment. The median
duration of delay was 2 weeks for everolimus and 2 weeks
for temsirolimus. In the moderate renal insufficiency group,
one patient had dose delay and dose reduction because of
grade 3 creatinine level elevation; this patient was receiving
bevacizumab plus temsirolimus as a first-line treatment.
None of the patients with severe renal insufficiency experi-
enced delays or required dose reductions. The median rela-
tive dose intensity during mTOR inhibitor treatment was
97% for the everolimus group and 98% for the temsiroli-
mus group. The treatment-related AEs are summarized in
Table 2. The most common non-hematologic and grade 3/4
AEs included stomatitis, fatigue, flu-like symptoms, and
anorexia as well as creatinine level elevation. The changes of
median GFR of patients according to the degree of renal 
insufficiency are summarized in Table 3.
3. Treatment outcomes
Of the 18 patients, three achieved partial response, the best
tumor response observed, of whom two received beva-
cizumab plus temsirolimus as a first-line treatment and one
received temsirolimus as a second-line treatment; 14 patients
showed stable disease. Overall response rate (ORR) was 16%
and disease-control rate was 94%. The median PFS duration
was 8 months (95% confidence interval [CI], 0 to 20.5) and
the median OS duration was 25 months (95% CI, 12.9 to 37.1).
In patients treated with mTOR inhibitors as a first-line treat-
ment, median PFS duration was 32 months (95% CI, not 
estimated) and the median OS duration was 32 months (95%
CI, 8.7 to 55.2). In patients treated with mTOR inhibitors as a
second-line treatment, median PFS duration was 4 months
(95% CI, 1.1 to 6.9) and the median OS duration was 18
months (95% CI, 6.9 to 29.1) (Fig. 1). We evaluated PFS and
OS rates in patients stratified according to the severity of
renal impairment. In the group with moderate/stage 3 renal
Table 2. Adverse events of all patients included in the study
Adverse event Grade 1-2 Grade 3-4 All grades
Fatigue 3 (16) 0 ( 3 (16)
General pain 1 (5) 0 ( 1 (5)
Skin color change 1 (5) 0 ( 1 (5)
Flu-like symptoms 3 (16) 0 ( 3 (16)
Taste alteration 1 (5) 0 ( 1 (5)
Pruritus 1 (5) 0 ( 1 (5)
General edema 1 (5) 0 ( 1 (5)
Stomatitis 9 (50) 0 ( 9 (50)
Anorexia/Nausea 3 (16) 0 ( 3 (16)
Dyspepsia 2 (11) 0 ( 2 (11)
Cough 2 (11) 0 ( 2 (11)
Laboratory abnormality
Anemia 1 (5) 0 ( 1 (5)
Creatinine level elevation 13 (72) 1 (5) 14 (77)
Hypertriglyceridemia 1 (5) 0 ( 1 (5)
Hyperglycemia 2 (11) 0 ( 2 (11)
Values are presented as number (%).
Table 3. Changes of median GFR of patients according to the degree of renal insufficiency
Variable Before mTOR During mTOR After mTORinhibitors treatment inhibitors treatment inhibitors treatment
Moderate renal impairment 51.9 (35-59.7) 36.3 (11-58.1) 49 (8.9-74)
Severe renal impairment 22 (18-26) 17 (15-19) 25 (25)
Values are presented as median (range). GFR, glomerular filtration rate; mTOR, mammalian target rapamycin.
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impairment, the median PFS duration was 5.0 months (95%
CI, 0 to 12.8) and the median OS duration was 25 months
(95% CI, 13.9 to 36.1).
We also evaluated PFS and OS rates in patients stratified
according to the mTOR inhibitor regimens. Patients treated
with temsirolimus and those treated with temsirolimus plus
bevacizumab were included in the analysis. In patients
treated with temsirolimus, the median PFS duration was 13
months (95% CI, 0 to 33.8) and the median OS duration was
18 months (95% CI, 0 to 38.8). In patients treated with
everolimus, the median PFS duration was 5 months (95% CI,
0 to 11.2) and the median OS was 24 months (95% CI, 9.2 to
38.8).
Discussion
In this retrospective study, patients with mRCC and renal
insufficiency treated with mTOR inhibitors showed median
PFS and OS durations of 8 and 25 months, respectively. The
ORR was 16% and the disease-control rate was 94%. Our
study thus yielded mixed data for mTOR inhibitor regimens.
Of 18 patients, five patients received mTOR inhibitors as a
first-line treatment and 13 as a second-line treatment. Eight
patients received temsirolimus, including bevacizumab plus
temsirolimus, and 10 patients received everolimus. There-
fore, it is difficult to compare the current phase III data with
those of other studies. However, we compared data with
those of three studies: a phase III study on everolimus in 
advanced renal cell carcinoma with normal renal function
that had progressed on other target therapies; one on tem-
sirolimus used as a first-line treatment; and one on tem-
sirolimus used as a second-line therapy after sunitinib [2-4].
In the results of previous phase III studies on mRCC patients
with normal renal function, median PFS was 4 months for
everolimus, 5.5 months for temsirolimus, and 4.3 months for
temsirolimus. The median OS with everolimus was not 
determined, 10.9 months for temsirolimus and 12.3 months
for temsirolimus [2-4]. In our study, both median PFS and
OS durations of mRCC patients with impaired renal function
were longer than those in mRCC patients with normal renal
function. The ORR in previous phase III studies with
everolimus and temsirolimus were 1% and 8%-8.6%, respec-
tively, lower than those in our study. The AEs of mTOR 
inhibitors in patients with renal insufficiency were similar to
those in mRCC patients with normal renal function treated
with mTOR inhibitors in previous phase III studies [2-4].
Therefore, mTOR inhibitors had the same efficacy in patients
with renal insufficiency, although this study was a retrospec-
tive study.
Because both everolimus and temsirolimus are cleared by
the liver and are mainly excreted in feces, all patients in our
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Fig. 1. Kaplan-Meier estimates of progression-free survival (A) and overall survival (B) durations in patients treated with
mammalian target rapamycin inhibitors as a second-line treatment (n=18). (A) Median progression-free survival: 4 months
(95% confidence interval [CI], 1.1 to 6.9). (B) Median overall survival: 18 months (95% CI, 6.9 to 29.1).
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study were started on the original dose regimen of eve-
rolimus and temsirolimus [16-18]. Only one patient experi-
enced a delay in dose and dose reduction due to grade 3 cre-
atinine level elevation during treatment. Dose intensity of
patients in our study was 97%-98%. Therefore, mTOR inhi-
bitors did not increase renal toxicity or non-renal toxicity in
mRCC patients with renal insufficiency.
Everolimus and temsirolimus are derivatives of sirolimus,
which is used in treatment of renal transplants; both drugs
are cleared by the liver and are mainly excreted in feces,
therefore we can overlook that mTOR inhibitors are safe for
patients with renal insufficiency. However, according to pre-
vious phase III studies and our study, the incidence of crea-
tinine level elevation in patients with normal renal function
or renal insufficiency treated with mTOR inhibitors was 
approximately 50% [4,8]. Also, renal function of mRCC 
patients may have deteriorated because of aging, chronic 
co-morbidities, and previous partial or radical nephrectomy
[12,13,19]. Therefore, careful monitoring of kidney function
is required in mRCC patients taking mTOR inhibitors.
However, although our study was a small retrospective
study that used heterogeneous treatments of mTOR inhi-
bitors, our results showed that the use of mTOR inhibitors
in patients with mRCC with renal insufficiency not requiring
dialysis was efficacious and did not increase toxicities.
Conclusion
mTOR inhibitors were found to be efficacious and safe for
the treatment of mRCC patients with renal insufficiency not
requiring dialysis, however the renal function of these 
patients should be monitored during treatment.
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